**Patients with sarcomere positive hypertrophic cardiomyopathy**

| D1 | D2 | D3 | D1 to D2 | D2 to D3 |
| --- | --- | --- | --- | --- |
| Obesity | Obstruction | NYHA III-IV | 1.78 (1.48 to 2.15) | 3.13 (2.29 to 4.28) |
| Obesity | Obstruction | Stroke | 1.78 (1.48 to 2.15) | 1.96 (1.04 to 3.69) |
| Obesity | Atrial fibrillation | NYHA III-IV | 1.44 (1.16 to 1.79) | 4.57 (3.28 to 6.38) |
| Hypertension | Obstruction | NYHA III-IV | 1.28 (1.03 to 1.59) | 3.02 (2.13 to 4.28) |
| Obstruction | Atrial fibrillation | NYHA III-IV | 2.22 (1.83 to 2.71) | 2.82 (1.83 to 4.34) |
| Obstruction | NYHA III-IV | Atrial fibrillation | 2.17 (1.73 to 2.72) | 2.23 (1.48 to 3.36) |
| Atrial fibrillation | NYHA III-IV | Stroke | 3.02 (2.38 to 3.84) | 2.59 (1.29 to 5.23) |
| Atrial fibrillation | LVSD | Composite VA | 3.4 (2.64 to 4.37) | 4.87 (2.37 to 10) |
| Atrial fibrillation | LVSD | Stroke | 3.4 (2.64 to 4.37) | 5.53 (2.67 to 11.46) |
| Atrial fibrillation | Composite VA | Stroke | 3.84 (2.71 to 5.44) | 3.4 (1.65 to 7.04) |
| LVSD | Atrial fibrillation | Stroke | 1.78 (1.27 to 2.49) | 2.68 (1.55 to 4.63) |
| LVSD | Stroke | Composite VA | 1.97 (1.13 to 3.43) | 5.03 (2.63 to 9.65) |